Surgical aortic valve replacement is the traditional open-heart operation to remove a diseased aortic valve and replace it with a new mechanical or biological (tissue) valve. It remains the gold standard for many patients, particularly younger individuals and those needing other cardiac surgery at the same time.
SAVR involves a cardiac surgeon opening the chest through a sternotomy (an incision down the breastbone), connecting the patient to a heart-lung bypass machine to temporarily take over the heart's pumping function, removing the diseased aortic valve, and sewing a new prosthetic valve in its place. The operation has been performed for over 60 years and has a well-established track record of durable outcomes.
Made of carbon and metal alloys, mechanical valves are extremely durable and can last a lifetime. However, they require lifelong blood-thinning medication (warfarin) to prevent blood clots from forming on the valve. This is a critical consideration — patients must have regular blood tests (INR monitoring) and accept the risks of both bleeding and clotting that come with anticoagulation. Mechanical valves are most often chosen for younger patients (under 50–55) who want to avoid reoperation.
Biological valves are made from animal tissue — most commonly bovine (cow) pericardium or porcine (pig) valve tissue — mounted on a frame. They do not typically require long-term warfarin, which is a significant advantage for quality of life. However, tissue valves degenerate over time (typically 10–20 years depending on age at implant) and may eventually require a second procedure — either a repeat surgery or, in many cases, a TAVR valve-in-valve procedure.
The decision between mechanical and tissue valves involves weighing durability against the burden of blood-thinning medication. Your age, lifestyle, ability to take warfarin reliably, and future plans all factor into this decision. Increasingly, tissue valves are being chosen because of the availability of valve-in-valve TAVR as a future option if the tissue valve wears out.
SAVR may be preferred for patients who are younger (generally under 65), those who need other heart surgery at the same time (such as bypass or repair of another valve), patients with anatomy not suitable for TAVR, those with active endocarditis (infection of the valve), and patients who prefer a mechanical valve and are willing to take lifelong warfarin.
The operation takes approximately 2–4 hours. Patients spend 1–2 days in the intensive care unit after surgery and typically remain in the hospital for 5–7 days total. Full recovery — including return to normal activities and driving — generally takes 6 to 12 weeks. Cardiac rehabilitation is strongly recommended after surgery and helps accelerate recovery, rebuild strength, and optimize long-term outcomes.
SAVR is a major open-heart operation, and risks include bleeding, infection, stroke, atrial fibrillation (an irregular heart rhythm common after cardiac surgery), kidney injury, and, rarely, death. The risk profile varies widely based on age, overall health, and the complexity of the operation. For appropriately selected patients, the results are excellent — with low mortality rates at experienced surgical centers.